甘李药业：目前公司与山德士的合作仍在持续稳步推进

Core Viewpoint - Gan Li Pharmaceutical (603087.SH) is progressing steadily in its collaboration with Sandoz, focusing on the commercialization of three biosimilars after receiving necessary approvals [1] Group 1: Collaboration with Sandoz - The company signed a commercial and supply agreement with Sandoz in 2018, which stipulates that Sandoz will handle the commercialization of three biosimilars (insulin glargine, insulin aspart, and insulin lispro) in the US, Europe, and other specific regions after they receive approval [1] - The collaboration with Sandoz is ongoing and continues to advance steadily [1] Group 2: Product Approval and Market Strategy - On January 15, 2026, the company's insulin glargine injection received marketing authorization from the European Commission [1] - The product is currently in the pre-commercialization phase, focusing on market access, channel layout, and logistics preparation, with commercial sales yet to begin [1] - The company emphasizes the importance of the European market as a strategic target and views this approval as a critical step in its internationalization strategy [1] - The company will adhere to disclosure obligations regarding commercialization progress in accordance with listing rules [1]